Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Exon 14 Mutation”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Not applicableStudy completedNCT06161051
What this trial is testing

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Who this might be right for
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Early research (Phase 1)Ended earlyNCT05435846
What this trial is testing

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer
Collin Blakely 3
Testing effectiveness (Phase 2)UnknownNCT02499614
What this trial is testing

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 80
Early research (Phase 1)Looking for participantsNCT05782361
What this trial is testing

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Who this might be right for
Advanced CancerNon Small Cell Lung Cancer
Institute of Cancer Research, United Kingdom 19
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 250
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06054191
What this trial is testing

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Who this might be right for
NSCLCBRAF V600 MutationMET Exon 14 Mutation
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Ended earlyNCT02920996
What this trial is testing

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Who this might be right for
Carcinoma, Non-Small-Cell LungSolid Tumor
Dana-Farber Cancer Institute 12
Testing effectiveness (Phase 2)WithdrawnNCT03147976
What this trial is testing

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
NantPharma, LLC
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Large-scale testing (Phase 3)Looking for participantsNCT05989542
What this trial is testing

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Who this might be right for
Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 136
Testing effectiveness (Phase 2)Ended earlyNCT04926831
What this trial is testing

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)Ended earlyNCT04323436
What this trial is testing

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Looking for participantsNCT06908993
What this trial is testing

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Who this might be right for
Advanced Non Small Cell Lung CancerMET Exon 14 Mutation
Intergroupe Francophone de Cancerologie Thoracique 133
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Post-approval studies (Phase 4)Study completedNCT05110196
What this trial is testing

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Who this might be right for
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals 50
Load More Results